SCHEMBL24254519

SCHEMBL24254519

Cc1ccc(S(=O)(=O)Nc2ccccc2)cc1NC(=O)Cc1ccc2ccccc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAT2 Q10469 1/20 0.57
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
ALDH1A1 P00352 3/20 0.55
POLB P06746 2/20 0.55
MAPT P10636 1/20 0.55
BLM P54132 1/20 0.55
PKM P14618 1/20 0.51
PKLR P30613 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
LMNA P02545 2/20 0.51
NR1H4 Q96RI1 1/20 0.50
GPR27 Q9NS67 1/20 0.49
NLRP3 Q96P20 1/20 0.49
GAA P10253 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
ATM Q13315 1/20 0.47
IDH2 P48735 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26188352 0.88 PKM (0.50) MGAT2MEN1KMT2AALDH1A1POLB
SCHEMBL24254503 0.86 MGAT2 (0.54) MGAT2MEN1KMT2AALDH1A1MAPT
SCHEMBL6765129 0.83 MGAT2 (0.56) MGAT2ALDH1A1POLBLMNAGPR27
SCHEMBL6762119 0.82 TMPRSS6 (0.57) MGAT2ALDH1A1POLBLMNAIDH2
SCHEMBL24254521 0.77 L3MBTL1 (0.52) MEN1KMT2AALDH1A1MAPTL3MBTL1
SCHEMBL8248238 0.75 HDAC1 (0.71) MEN1KMT2AALDH1A1PKMPKLR
SCHEMBL9367263 0.75 NR1H4 (0.83) MEN1KMT2AALDH1A1MAPTL3MBTL1
SCHEMBL20021987 0.73 PGR (0.77) MEN1KMT2AALDH1A1MAPTPKM
SCHEMBL28396503 0.73 PGR (0.77) MEN1KMT2AALDH1A1MAPTPKM
SCHEMBL29549847 0.73 PGR (0.77) MEN1KMT2AALDH1A1MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 MGAT2 3318/4885MEN1 3058/4885KMT2A 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.